Find Pimavanserin Tartrate manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

KDMF

KDMF

0

VMF

NDC API

API REF. PRICE (USD/KG)

MARKET PLACE

0

FDF

FINISHED DOSAGE FORMULATIONS

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

PATENTS & EXCLUSIVITIES

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

Annual Reports

NA

Finished Drug Prices

NA

78 RELATED EXCIPIENT COMPANIES

139EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 706779-91-1, Acp-103, 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-methylpiperidin-4-yl)urea, Pimavanserin [inn], Pimavanserin free base, Jz963p0dik
Molecular Formula
C25H34FN3O2
Molecular Weight
427.6  g/mol
InChI Key
RKEWSXXUOLRFBX-UHFFFAOYSA-N
FDA UNII
JZ963P0DIK

Pimavanserin Tartrate
Psychotic symptoms associated with Parkinson's disease (PD) are relatively common, reducing quality of life and prognosis for individuals with PD. Pimavanserin (ACP-103), marketed under the trade name Nuplazid, is a drug developed by Acadia Pharmaceuticals for the treatment of psychosis related to Parkinson's disease. Due to its actions at serotonin receptors and lack of effects on dopamine receptors, pimavanserin treats hallucinations and delusions without causing extrapyramidal symptoms. It was initially approved by the FDA in 2016 and is now under review as a potential treatment for dementia related psychosis. As of April 2021, FDA approval has not been granted for this indication, despite previous breakthrough designation.
Pimavanserin is an Atypical Antipsychotic.
1 2D Structure

Pimavanserin Tartrate

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
1-[(4-fluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)-3-[[4-(2-methylpropoxy)phenyl]methyl]urea
2.1.2 InChI
InChI=1S/C25H34FN3O2/c1-19(2)18-31-24-10-6-20(7-11-24)16-27-25(30)29(23-12-14-28(3)15-13-23)17-21-4-8-22(26)9-5-21/h4-11,19,23H,12-18H2,1-3H3,(H,27,30)
2.1.3 InChI Key
RKEWSXXUOLRFBX-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CC(C)COC1=CC=C(C=C1)CNC(=O)N(CC2=CC=C(C=C2)F)C3CCN(CC3)C
2.2 Other Identifiers
2.2.1 UNII
JZ963P0DIK
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Acp 103

2. Acp-103

3. Acp103

4. Bis(1-(4-fluorobenzyl)-1-(1-methylpiperidin-4-yl)-3-(4-(2-methylpropoxy)benzyl)urea) (2r,3r)-2,3-dihydroxybutanedioate

5. N-(4-fluorophenylmethyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl)carbamide

6. Nuplazid

7. Pimavanserin Tartrate

8. Urea, N-((4-fluorophenyl)methyl)-n-(1-methyl-4-piperidinyl)-n'-((4-(2-methylpropoxy)phenyl)methyl)-, (2r,3r)-2,3-dihydroxybutanedioate (2:1)

2.3.2 Depositor-Supplied Synonyms

1. 706779-91-1

2. Acp-103

3. 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-methylpiperidin-4-yl)urea

4. Pimavanserin [inn]

5. Pimavanserin Free Base

6. Jz963p0dik

7. 706779-91-1 (free Base)

8. 1-[(4-fluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)-3-[[4-(2-methylpropoxy)phenyl]methyl]urea

9. N-(4-fluorophenylmethyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl) Carbamide

10. Unii-jz963p0dik

11. N-(4-fluorophenylmethyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl)carbamide

12. 706782-28-7

13. Pimanavserin

14. Methyltrimethylacetate

15. Ac-5273

16. Pimavanserin [mi]

17. Pimavanserin(acp-103)

18. Pimavanserin [who-dd]

19. Schembl675165

20. Nuplazid (proposed Trade Name)

21. Gtpl8423

22. Chembl2111101

23. Dtxsid90990906

24. Chebi:133017

25. Bdbm139370

26. Hms3742a03

27. Bcp11618

28. Ex-a4895

29. Mfcd09953792

30. Zinc16159083

31. Akos015902593

32. Cs-3378

33. Db05316

34. Me-0240

35. Sb16963

36. Ncgc00390656-01

37. Ncgc00390656-02

38. Hy-14557

39. B8019

40. Ft-0653701

41. A14434

42. 779p911

43. A836958

44. J-503297

45. Q7194603

46. N-[(4-fluorophenyl)methyl]-n-(1-methyl-4-piperidinyl)-n'-[[4-(2-methylpropoxy)phenyl]methyl]urea;

47. N-[(4-fluorophenyl)methyl]-n-(1-methylpiperidin-4-yl)-n'-{[4-(2-methylpropoxy)phenyl]methyl}urea

2.4 Create Date
2006-10-25
3 Chemical and Physical Properties
Molecular Weight 427.6 g/mol
Molecular Formula C25H34FN3O2
XLogP34.5
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count4
Rotatable Bond Count8
Exact Mass427.26350550 g/mol
Monoisotopic Mass427.26350550 g/mol
Topological Polar Surface Area44.8 Ų
Heavy Atom Count31
Formal Charge0
Complexity523
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Pimavanserin is indicated for the treatment of hallucinations and delusions associated with Parkinsons disease psychosis.


Treatment of schizophrenia and other psychotic disorders


5 Pharmacology and Biochemistry
5.1 Pharmacology

Pimavanserin's unique actions on serotonin receptors improve symptoms of hallucinations and delusions associated with Parkinson's disease. In clinical studies, 80.5% of individuals treated with pimavanserin reported improvement in symptoms. Pimavanserin does not worsen motor functioning in patients with Parkinson's disease psychosis.


5.2 MeSH Pharmacological Classification

Antiparkinson Agents

Agents used in the treatment of Parkinson's disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists. (See all compounds classified as Antiparkinson Agents.)


Antipsychotic Agents

Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. (See all compounds classified as Antipsychotic Agents.)


Serotonin 5-HT2 Receptor Antagonists

Drugs that bind to but do not activate SEROTONIN 5-HT2 RECEPTORS, thereby blocking the actions of SEROTONIN or SEROTONIN 5-HT2 RECEPTOR AGONISTS. Included under this heading are antagonists for one or more specific 5-HT2 receptor subtypes. (See all compounds classified as Serotonin 5-HT2 Receptor Antagonists.)


5.3 FDA Pharmacological Classification
5.3.1 Active Moiety
PIMAVANSERIN
5.3.2 FDA UNII
JZ963P0DIK
5.3.3 Pharmacological Classes
Established Pharmacologic Class [EPC] - Atypical Antipsychotic
5.4 ATC Code

N - Nervous system

N05 - Psycholeptics

N05A - Antipsychotics

N05AX - Other antipsychotics

N05AX17 - Pimavanserin


5.5 Absorption, Distribution and Excretion

Absorption

The median Tmax of pimavanserin in clinical studies was 6 hours, regardless of the dose. Bioavailability of an oral tablet of pimavanserin and a solution were almost identical. The major active circulating N-desmethylated metabolite, AC-279, has a median Tmax of 6 hours.


Route of Elimination

About 0.55% of a 34 mg oral dose was excreted unchanged in the urine and 1.53% was eliminated in feces within 10 days. Less than 1% of the administered dose and its active metabolite AC-279 were recovered in urine during clinical studies.


Volume of Distribution

Following administration of a single dose of 34 mg, the average apparent volume of distribution was 2173 L in clinical studies.


5.6 Metabolism/Metabolites

Pimavanserin is mainly metabolized CYP3A4 and CYP3A5 hepatic cytochrome enzymes, and to a lesser extent by CYP2J2, CYP2D6, and other cytochrome and flavin-containing monooxygenase enzymes. CYP3A4 metabolizes pimavanserin to its major active metabolite, AC-279.


5.7 Biological Half-Life

The average plasma half-lives for pimavanserin and its active metabolite (AC-279) are estimated at 57 hours and 200 hours, respectively.


5.8 Mechanism of Action

Parkinson's disease psychosis (PDP) is a imbalance of serotonin and dopamine from disruption of the normal balance between the serotonergic and dopaminergic receptors and neurotransmitters in the brain. The mechanism by which pimavanserin treats hallucinations and delusions associated with Parkinsons disease psychosis is not fully established. It is possible that pimavanserin acts via inverse agonist and antagonist activity at serotonin 5-HT2A receptors with limited effects on serotonin 5-HT2C receptors. Pimavanserin is an inverse agonist and antagonist of serotonin 5-HT2A receptors with high binding affinity, demonstrating low binding affinity to serotonin 5-HT2C receptors. In addition, this drug exhibits low affinity binding to sigma 1 receptors. Pimavanserin lacks activity at muscarinic, dopaminergic, adrenergic, and histaminergic receptors, preventing various undesirable effects typically associated with antipsychotics.


API Reference Price

read-more
read-more
[{"dataSource":"API Export","activeIngredients":"","year":"2021","qtr":"Q2","strtotime":1623436200,"product":"PIMAVANSERIN TARTRATE (TAX INV NO:BPCI\/2 1-22\/04E DT:04\/06\/2021","address":"PLOT?NO.?193,?HOUSE?NO.?5-35\/50,PRASHANT?NAGAR,?KUKATPALLY,","city":"HYDERABAD,?AP","supplier":"BIOPHORE INDIA PHARMACEUTICALS PVT LTD","supplierCountry":"INDIA","foreign_port":"ISTANBUL","customer":"PHARMACTIVE ILAC SAN ","customerCountry":"TURKEY","quantity":"2.00","actualQuantity":"2","unit":"KGS","unitRateFc":"15956.3","totalValueFC":"31263.5","currency":"USD","unitRateINR":1149648.5,"date":"12-Jun-2021","totalValueINR":"2299297","totalValueInUsd":"31263.5","indian_port":"HYDERABAD AIR","hs_no":"29333990","bill_no":"2373706","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"TURKEY","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"PLOT?NO.?193,?HOUSE?NO.?5-35\/50,PRASHANT?NAGAR,?KUKATPALLY,, HYDERABAD,?AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2021","qtr":"Q3","strtotime":1631903400,"product":"PIMAVANSERIN TARTRATE (TAX INV NO:BPVCI","address":"PLOT?NO.?193,?HOUSE?NO.?5-35\/50,PRASHANT?NAGAR,?KUKATPALLY,","city":"HYDERABAD,?AP","supplier":"BIOPHORE INDIA PHARMACEUTICALS PVT LTD","supplierCountry":"INDIA","foreign_port":"ISTANBUL","customer":"ARDI FARMA ILAC PAZARLAMA TICARET LTD STI","customerCountry":"TURKEY","quantity":"0.50","actualQuantity":"0.5","unit":"KGS","unitRateFc":"15000","totalValueFC":"7286.9","currency":"USD","unitRateINR":1072000,"date":"18-Sep-2021","totalValueINR":"536000","totalValueInUsd":"7286.9","indian_port":"HYDERABAD AIR","hs_no":"29333990","bill_no":"4687210","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"TURKEY","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"PLOT?NO.?193,?HOUSE?NO.?5-35\/50,PRASHANT?NAGAR,?KUKATPALLY,, HYDERABAD,?AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2021","qtr":"Q4","strtotime":1640025000,"product":"PIMAVANSERIN TARTRATE IH","address":"8-3-166\/182, A BLOCK, NORTH WING,, 105-108, IST FLOOR CHALLA ESTATES,","city":"ERRADADDA,TELANGANA","supplier":"DASAMI LAB PRIVATE ","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES, BA","customer":"BAGO GROUP","customerCountry":"ARGENTINA","quantity":"0.20","actualQuantity":"0.2","unit":"KGS","unitRateFc":"4000","totalValueFC":"662.9","currency":"USD","unitRateINR":250000,"date":"21-Dec-2021","totalValueINR":"50000","totalValueInUsd":"662.9","indian_port":"HYDERABAD AIR","hs_no":"29333990","bill_no":"6905890","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"8-3-166\/182, A BLOCK, NORTH WING,, 105-108, IST FLOOR CHALLA ESTATES,, ERRADADDA,TELANGANA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q1","strtotime":1646245800,"product":"PIMAVANSERIN TARTRATE IH","address":"8-3-166\/182, A BLOCK, NORTH WING,, 105-108, IST FLOOR CHALLA ESTATES,","city":"ERRADADDA,TELANGANA","supplier":"DASAMI LAB PRIVATE ","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES, BA","customer":"BAGO GROUP","customerCountry":"ARGENTINA","quantity":"18.00","actualQuantity":"18","unit":"KGS","unitRateFc":"1794.5","totalValueFC":"30202.2","currency":"USD","unitRateINR":127888.88888888889,"date":"03-Mar-2022","totalValueINR":"2302000","totalValueInUsd":"30202.2","indian_port":"HYDERABAD AIR","hs_no":"29333990","bill_no":"8671985","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"8-3-166\/182, A BLOCK, NORTH WING,, 105-108, IST FLOOR CHALLA ESTATES,, ERRADADDA,TELANGANA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q1","strtotime":1648405800,"product":"PIMAVANSERIN TARTRATE (II)","address":"MSN HOUSE,PLOT NO.C-24,INDUSTRIAL E SANATH NAGAR,HYDERABAD","city":"HYDERABAD TS","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"ISTANBUL","customer":"PHARMACTIVE YLAC SAN. VE TIC.A.S","customerCountry":"TURKEY","quantity":"0.20","actualQuantity":"0.2","unit":"KGS","unitRateFc":"15000","totalValueFC":"2965.1","currency":"USD","unitRateINR":1130000,"date":"28-Mar-2022","totalValueINR":"226000","totalValueInUsd":"2965.1","indian_port":"HYDERABAD AIR","hs_no":"29333200","bill_no":"9267682","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"TURKEY","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"MSN HOUSE,PLOT NO.C-24,INDUSTRIAL E SANATH NAGAR,HYDERABAD, HYDERABAD TS","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q4","strtotime":1669314600,"product":"PIMAVANSERIN TARTRATE IH","address":"8-3-166\/182, A BLOCK, NORTH WING,, 105-108, IST FLOOR CHALLA ESTATES,","city":"ERRADADDA,TELANGANA","supplier":"DASAMI LAB PRIVATE ","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES, BA","customer":"BAGO GROUP","customerCountry":"ARGENTINA","quantity":"5.00","actualQuantity":"5","unit":"KGS","unitRateFc":"1988.5","totalValueFC":"9447.1","currency":"USD","unitRateINR":154200,"date":"25-Nov-2022","totalValueINR":"771000","totalValueInUsd":"9447.1","indian_port":"HYDERABAD AIR","hs_no":"29333990","bill_no":"5729249","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"8-3-166\/182, A BLOCK, NORTH WING,, 105-108, IST FLOOR CHALLA ESTATES,, ERRADADDA,TELANGANA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1711391400,"product":"PIMAVANSERIN TARTRATE","address":"8-3-166\/182, A BLOCK, NORTH WING,,","city":"ERRADADDA,TELANGANA","supplier":"DASAMI LAB PRIVATE ","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES, BA","customer":"TO THE ORDER OF","customerCountry":"ARGENTINA","quantity":"5.00","actualQuantity":"5","unit":"KGS","unitRateFc":"1700","totalValueFC":"7936.4","currency":"USD","unitRateINR":131801,"date":"26-Mar-2024","totalValueINR":"659005","totalValueInUsd":"7936.4","indian_port":"Hyderabad Air","hs_no":"29333990","bill_no":"8622142","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"8-3-166\/182, A BLOCK, NORTH WING,,, ERRADADDA,TELANGANA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1722882600,"product":"PIMAVANSERIN TARTRATE","address":"8-3-166\/182, A BLOCK, NORTH WING,,","city":"ERRADADDA,TELANGANA","supplier":"DASAMI LAB PRIVATE ","supplierCountry":"INDIA","foreign_port":"MONTEVIDEO -","customer":"MEGA LABS S.A.","customerCountry":"URUGUAY","quantity":"2.00","actualQuantity":"2","unit":"KGS","unitRateFc":"3200","totalValueFC":"5891.1","currency":"USD","unitRateINR":247070,"date":"06-Aug-2024","totalValueINR":"494140","totalValueInUsd":"5891.1","indian_port":"Hyderabad Air","hs_no":"29333990","bill_no":"2994633","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"URUGUAY","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"8-3-166\/182, A BLOCK, NORTH WING,,, ERRADADDA,TELANGANA","customerAddress":""}]
12-Jun-2021
06-Aug-2024
KGS
overview
Loading...

Average Price (USD/KGS)

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

API Imports and Exports

Importing Country Total Quantity
(KGS)
Average Price
(USD/KGS)
Number of Transactions

Upgrade, download data, analyse, strategize, subscribe with us contact

Related Excipient Companies

Upload your portfolio for free, ask us

Excipients by Applications

Click here to find the perfect excipient manufacturers by their capabilities

Fillers, Diluents & Binders

read-more
read-more

Direct Compression

read-more
read-more

Lubricants & Glidants

read-more
read-more

Co-Processed Excipients

read-more
read-more

Thickeners and Stabilizers

read-more
read-more

Disintegrants & Superdisintegrants

read-more
read-more

Coating Systems & Additives

read-more
read-more

Taste Masking

read-more
read-more

Granulation

read-more
read-more

Controlled & Modified Release

read-more
read-more

Film Formers & Plasticizers

read-more
read-more

Chewable & Orodispersible Aids

read-more
read-more

Coloring Agents

read-more
read-more

Topical

read-more
read-more

Rheology Modifiers

read-more
read-more

Emulsifying Agents

read-more
read-more

Parenteral

read-more
read-more

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Pimavanserin Tartrate Manufacturers

A Pimavanserin Tartrate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Pimavanserin Tartrate, including repackagers and relabelers. The FDA regulates Pimavanserin Tartrate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Pimavanserin Tartrate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Pimavanserin Tartrate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Pimavanserin Tartrate Suppliers

A Pimavanserin Tartrate supplier is an individual or a company that provides Pimavanserin Tartrate active pharmaceutical ingredient (API) or Pimavanserin Tartrate finished formulations upon request. The Pimavanserin Tartrate suppliers may include Pimavanserin Tartrate API manufacturers, exporters, distributors and traders.

click here to find a list of Pimavanserin Tartrate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Pimavanserin Tartrate USDMF

A Pimavanserin Tartrate DMF (Drug Master File) is a document detailing the whole manufacturing process of Pimavanserin Tartrate active pharmaceutical ingredient (API) in detail. Different forms of Pimavanserin Tartrate DMFs exist exist since differing nations have different regulations, such as Pimavanserin Tartrate USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Pimavanserin Tartrate DMF submitted to regulatory agencies in the US is known as a USDMF. Pimavanserin Tartrate USDMF includes data on Pimavanserin Tartrate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Pimavanserin Tartrate USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Pimavanserin Tartrate suppliers with USDMF on PharmaCompass.

Pimavanserin Tartrate WC

A Pimavanserin Tartrate written confirmation (Pimavanserin Tartrate WC) is an official document issued by a regulatory agency to a Pimavanserin Tartrate manufacturer, verifying that the manufacturing facility of a Pimavanserin Tartrate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Pimavanserin Tartrate APIs or Pimavanserin Tartrate finished pharmaceutical products to another nation, regulatory agencies frequently require a Pimavanserin Tartrate WC (written confirmation) as part of the regulatory process.

click here to find a list of Pimavanserin Tartrate suppliers with Written Confirmation (WC) on PharmaCompass.

Pimavanserin Tartrate NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Pimavanserin Tartrate as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Pimavanserin Tartrate API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Pimavanserin Tartrate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Pimavanserin Tartrate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Pimavanserin Tartrate NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Pimavanserin Tartrate suppliers with NDC on PharmaCompass.

Pimavanserin Tartrate GMP

Pimavanserin Tartrate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Pimavanserin Tartrate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Pimavanserin Tartrate GMP manufacturer or Pimavanserin Tartrate GMP API supplier for your needs.

Pimavanserin Tartrate CoA

A Pimavanserin Tartrate CoA (Certificate of Analysis) is a formal document that attests to Pimavanserin Tartrate's compliance with Pimavanserin Tartrate specifications and serves as a tool for batch-level quality control.

Pimavanserin Tartrate CoA mostly includes findings from lab analyses of a specific batch. For each Pimavanserin Tartrate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Pimavanserin Tartrate may be tested according to a variety of international standards, such as European Pharmacopoeia (Pimavanserin Tartrate EP), Pimavanserin Tartrate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Pimavanserin Tartrate USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty